Published in Eur J Clin Microbiol on June 01, 1987
Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med (1992) 3.91
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr (1981) 3.42
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med (1991) 3.16
Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med (1986) 2.63
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Varicella vaccine in pregnancy. BMJ (1996) 2.38
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol (1997) 2.34
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A (1998) 2.22
Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med (1984) 2.22
Reliability of a history of previous varicella infection in adults. JAMA (1997) 2.13
Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med (1987) 1.99
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr (1992) 1.94
Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med (1986) 1.94
Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis (2001) 1.90
Cesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. JAMA (1993) 1.84
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 1.72
Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med (1988) 1.67
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody. Infect Immun (1983) 1.65
Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol (1989) 1.64
Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol (2001) 1.55
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis (1992) 1.45
Comparison of a micromethod for performance of the serum bactericidal test with the standard tube dilution method. Antimicrob Agents Chemother (1979) 1.44
Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis (1991) 1.43
Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections. J Clin Microbiol (1980) 1.41
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol (2000) 1.30
Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis (1988) 1.29
IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol (1999) 1.28
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis (1990) 1.17
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Fusarium brain abscess. Case report. J Neurosurg (1983) 1.17
Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis (1983) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun (1980) 1.12
Storage and transport of cultures for Herpes simplex virus, type 2. Am J Clin Pathol (1979) 1.11
Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr (1982) 1.11
Measurement of amphotericin B in serum or plasma by high-performance liquid chromatography. J Chromatogr (1983) 1.10
Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis (1989) 1.08
Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J (1990) 1.08
Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics (1984) 1.08
Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob Agents Chemother (1978) 1.08
Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J Infect Dis (1976) 1.06
Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J Infect Dis (1987) 1.06
Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol (1991) 1.05
Varicella-zoster virus infection of a human CD4-positive T-cell line. Virology (2000) 1.04
Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis. J Pediatr (1979) 1.04
Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J Infect Dis (1998) 1.04
The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. J Infect Dis (1999) 1.04
Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis (1992) 1.02
Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med (1982) 1.02
Prophylactic fluconazole and Candida krusei infections. N Engl J Med (1992) 1.01
Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis (1997) 1.01
Yersinia pseudotuberculosis septicemia. Am J Dis Child (1979) 1.00
Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells. J Virol (2000) 1.00
Neonatal herpes simplex infection in the absence of mucocutaneous lesions. J Pediatr (1982) 1.00
Eikenella corrodens empyema in children. Am J Dis Child (1981) 0.99
Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. J Clin Microbiol (1990) 0.99
Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis (1998) 0.99
Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids. J Infect Dis (1998) 0.98
Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. Am J Med (1982) 0.98
Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J (1989) 0.97
Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol (2001) 0.97
Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. J Gen Virol (1992) 0.96
Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis (1998) 0.95
Brain abscesses in infants and children. Pediatr Infect Dis (1985) 0.92
Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol (1997) 0.92
Open lung biopsy in immunocompromised children with pulmonary infiltrates. Am J Dis Child (1984) 0.92
Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther (1992) 0.92
Prophylactic sulfamethoxazole and trimethoprim in ventriculoperitoneal shunt surgery. A double-blind, randomized, placebo-controlled trial. JAMA (1984) 0.91
Genital herpes and the pregnant woman. Curr Clin Top Infect Dis (1989) 0.91
Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics (2000) 0.91
Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects. J Clin Microbiol (1983) 0.91
T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J Infect Dis (1996) 0.90